Health ❯ Healthcare ❯ Regulatory Affairs
Drug Approval Process Medical Devices Drug Indications Drug Approvals Drug Development Drug Safety Clinical Trials Biologics License Applications Breakthrough Therapy Designation Biologics License Application Novo Nordisk New Drug Applications Orphan Drug Designation Fast Track Designation New Drug Approvals Accelerated Approval Process Label Expansions Liso-cel Approval National Priority Voucher Program Alzheimer's Disease Drugs COVID-19 Vaccine Approvals Drug Labeling Brensocatib Approval Accelerated Approval Drug Safety and Efficacy Cancer Drugs Expedited Drug Approval Breakthrough Devices Drug Inventory mCOMBRIAX Semaglutide 7.2 mg Accelerated Approval Pathway Drug Efficacy Medical Innovations Drug Treatments Medical Device Clearance Priority Review Designation Drug Development Timeline Clinical Safety and Efficacy Belzutifan Miplyffa Breakthrough Device Designation FDA Drug Designations Cemiplimab Approval Fast-Track Programs Vaccine Candidates Safety Advisories Drug Applications Gene Therapies Omidubicel-onlv Vaccine Approvals Drug Formulations Expanded Access Programs New Drug Treatments New Therapies Drug Designations Gene Therapy Glaukos Corp Drug Combinations Medical Technology Novel Therapies Onasemnogene Abeparvovec Zopapogene Imadenovec-Drba Medical Device Approvals Drug Filings Medical Algorithms Biologics License Application (BLA)
Want to see what podcasts are saying about this topic? Search across 135K+ podcasts. Explore Radar
The agency cleared the label on Aug. 28, 2026 after Lilly’s head‑to‑head SURPASS‑CVOT showed a modest cardiovascular advantage over Trulicity, a result that broadens Mounjaro’s clinical and commercial role.
